Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 291 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: basal insulin Clear all
Completed Phase 2 Interventional Results available

Intensive Glycemic Control for Congestive Heart Failure Exacerbation

NCT00812253
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes Mellitus
Interventions
Intravenous insulin, Subcutaneous insulin
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 23, 2026, 4:50 AM EDT
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 23, 2026, 4:50 AM EDT
Withdrawn Not applicable Interventional

Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

NCT02144441
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
glargine and aspart
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 23, 2026, 4:50 AM EDT
Completed No phase listed Observational

The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes

NCT00147342
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 23, 2026, 4:50 AM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 4:50 AM EDT
Completed No phase listed Observational

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

NCT01548222
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

NCT01240200
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Glargine, glargine via insulin pen
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

NCT02772783
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
high GI meal, low GI meal, euglycemic insulin clamp, primed-variable insulin infusion
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

NCT05013229
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
66
States / cities
Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 23, 2026, 4:50 AM EDT
Terminated Not applicable Interventional

Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]

NCT03980236
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Livongo-Insulia Study App
Device
Lead sponsor
Livongo Health
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

NCT01499095
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes

NCT01409239
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient
Interventions
Intravenous insulin, Subcutaneous Insulin
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

NCT00954447
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
47
States / cities
Escondido, California • Fresno, California • Greenbrae, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 23, 2026, 4:50 AM EDT
Terminated Phase 4 Interventional

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
h-Patch
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 4 Interventional

Insulin Therapy in the Hospital Comparing Two Protocols

NCT00841919
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents

NCT01890954
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

NCT00978627
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 23, 2026, 4:50 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 4:50 AM EDT
Not listed Phase 4 Interventional

Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices

NCT02361489
View directory record Official record
Conditions
Diabetes Type II
Interventions
V-Go
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 23, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 23, 2026, 4:50 AM EDT